ZYNE

Q3'20

Last Updated:

Zynerba Pharmaceuticals

At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to transform the quality of lives of patients and their families as they battle these conditions.

Our goal is to advance the science of therapeutic cannabinoids, and to improve the lives of patients battling severe neuropsychiatric conditions including Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

Our approach is to utilize our pharmaceutically-manufactured, penetration-enhanced transdermal cannabinoid product candidate to modulate pathways in the central nervous system that, when disrupted, cause certain neurological diseases. By doing so, we hope to provide new treatment options for patients battling certain rare neuropsychiatric diseases.

Cash

$64.3M

Burn Rate (Quarterly)

-$9M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Zygel (ZYN002 CBD Gel)

Fragile X Syndrome (FXS)

Phase 3 (FDA Meeting to Discuss Results)

Q4 2020

Zygel (ZYN002 CBD Gel)

Developmental and epileptic encephalopathies (DEE)

Phase 2 (Corporate Update)

Q4 2020

Zygel (ZYN002 CBD Gel)

Autism spectrum disorder (ASD)

Phase 2 (FDA Meeting)

Q4 2020

Zygel (ZYN002 CBD Gel)

22q11.2 deletion syndrome (22q)

Phase 2 (Data)

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon